were the first to report that BRAF mutations were confined to patients with papillary thyroid carcinoma (PTC) or to those with poorly differentiated or anaplastic thyroid cancers arising from previous PTC. This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.